Surgery – Diagnostic testing – Detecting nuclear – electromagnetic – or ultrasonic radiation
Reexamination Certificate
2005-05-31
2005-05-31
Smith, Ruth S. (Department: 3737)
Surgery
Diagnostic testing
Detecting nuclear, electromagnetic, or ultrasonic radiation
C600S425000, C600S427000, C600S437000, C600S443000, C600S562000, C378S037000, C436S063000, C435S004000
Reexamination Certificate
active
06901278
ABSTRACT:
The subject invention provides methods for evaluating women in designing appropriate menopausal and postmenopausal therapies to match the particular needs of the individual. In one embodiment, the subject invention provides methods for evaluating particular factors in menopausal and postmenopausal women that are then taken into account in identifying a therapy program to promote good health and reduce the risk of any adverse health effects as a result of the therapy, specifically the role of hormone induced/associated breast cancer. More specifically, the subject invention includes methods for evaluating menopausal and postmenopausal women to determine whether hormone replacement therapy is appropriate in this regard, and if so, the specifics of how that therapy is to be administered. The subject invention, by incorporating various factors into a comprehensive, function breast hormone profile, allows for the identification of untreated women with estrogen-related metabolic abnormalities that may increase the risk of breast cancer. The subject invention determines specific therapies to correct and/or inhibit the aberrant biosynthetic pathways, and thus, the risk of cancer.
REFERENCES:
Boyd, N.F. et al. (Sep. 19, 2002) “Heritability of Mammorgraphic Density, A Risk Factor for Breast Cancer,”N. Engl. J. Med. 347(12):886-894.
Cauley, J.A. et al. (Feb. 16, 1999) “Elevated Serum Estradiol and Testosterone Concentrations are Associated with a High Risk for Breast Cancer. Study of Osteoporotic Fractures Research Group,”Ann. Intern. Med. 130(4 Pt 1):270-277.
Clemons, M. and P. Gross (Jan. 25, 2001) “Estrogen and the Risk of Breast Cancer”N. Engl. J. Med. 344(4):276-285.
Beral, V. et al. (Collaborative Group on Hormonal Factors in Breast Cancer, Oct. 11, 1997)Lancet, 350:1047-1059.
Cushman, M. et al. (Jun. 1, 1995) “Synthesis, Antitubulin and Antimitotic Activity, and Cytotoxicity of Analogs of 2-methoxyestradiol, an Endogenous Mammalian Metabolite of Estradiol that Inhibits Tubulin Polymerization by Binding to the Colchicine Binding Site”J. Med. Chem. 38:2041-2049.
Fotsis, J. et al. (Mar. 17, 1994) “2-methoxyestradiol, an Endogenous Estrogen Metabolite, Inhibits Angiogensis and Suppresses Tumor Growth,”Nature368:237-239.
Gajdos, C. et al. (Apr. 2000) “Breast Cancer Diagnosed During Hormone Replacement Therapy”Obstet. Gynecol. 95(4):513:518.
Gapstur, S.M. et al. (Jun. 9, 1999) “Hormone Replacement Therapy and Risk of Breast Cancer with a Favorable Histology: Results of the Iowa Women's Health Study”JAMA281(22):2091-2097.
Guttmacher, A.E. and F.S. Collins (Nov. 7, 2002) “Genomic Medicine—a Primer”N. Eng. J. Med. 347(19):1512-1520.
Hayes et al. (Sep. 1996) “17 Beta-Estradiol Hydroxylation Catalyzed by Human Cytochrome p450 1B1”Proc. Natl. Acad. Sci. U.S.A., 93:9776-9781.
Huang et al. (Oct. 1, 1999) “Breast Cancer Risk Associated With Genotype Polymorphism of the Estrogen-Metabolizing Genes CYP17, CYP1A1, and COMT: A Multigenic Study on Cancer Susceptibility”Cancer Res. 59:4870-4875.
Kristensen VN (Feb. 2001) et al. “High-Throughput Methods for Dection of Genetic Variation”BioTechniques30(2):318-332.
Lavigne et al. (Dec. 15, 1997) “An Association Between the Allele Coding for a Low Activity Variant of Catechol-O-Methyltransferase and the Risk for Breast Cancer”Cancer Res. 57:5493-5497.
Lieber, J.G. et al. (Jun. 20, 1995) “Adenovirus-Mediated Urokinase Gene Transfer Indues Liver Regeneration and Allows for Efficient Retrovirus Transduction of Hepatocytes in vivo”Proc. Natl. Acad. Sci. U.S.A. 92(13):6210-6214.
Lippert, T.H. et al. (1998) “Estradiol Metabolism During Oral and Transdermal Estradiol Replacement Therapy in Postmenopausal Women”Horm. Metab. Res. 30(9):598-600.
Lobo, R.A. (Mar. 1987) “Androgen Excess and the Infertile Woman”Obstet. Gynecol. Clin. North Am. 14(1):143-167.
Nebert, D.W. and D.W. Russell, “Clinical Importance of the Cytochromes P450,”Lancet, Oct. 12, 2002, pp. 1155-1162, vol. 360.
Pasqualini, J.R.. et al. (1996) “Concentrations of Estrone, Estradiol, and Estrone Sulfate and Evaluation of Sulfatase and Aromatase Activities in Pre- and Postmenopausal Breast Cancer Patients”J. Clin. Endocrinol. Metab. 81(4):1460-1464.
Ruder, Henry J. et al. (1972) “Estrone Sulfate: Production Rate and Metabolism in Man”J. Clin. Invest. 51:1020-1023.
Siegelmann-Danieli, N. and K.H. Butetow (1999) “Constitutional Genetic Variation at the Human Aromatase Gene (Cyp19) and Breast Cancer Risk”Br. J. Cancer79(3/4):456-463.
Ursin et al. (Jun. 16, 1999) “Urinary 2-Hydroxyestrone/16alpha-Hydroxyestrone Ratio and Risk of Breast Cancer in Postmenopausal Women”J. Natl. Cancer Inst. 9(12):1067-1072.
van de Vijver et al. (Dec. 19, 2002) “A Gene-Expression Signature as a Predictor of Survival in Breast Cancer”N. Engl. J. Med. 347(25):1999-2009.
Vehkavaara, S. et al. (Nov. 28, 2000) “Differential Effects of Oral and Transdermal Estogen Replacement Therapy on Endothelial Function in Postmenopausal Women”Circulation102:2687-2693.
Vermeulen, A. et al. (1986) (Proc. of the XII International Study Group for Steroid Hormones, Rome, Dec. 2-4, 1985) “Steroid Dynamics in the Normal and Carcinomatous Mammary Gland”J. Steroid Biochem. 25:799-802, vol. 25.
West, M. et al. (Sep. 25, 2001) “Predicting the Clinical Status of Human Breast Cancer by Using Gene Expression Profiles”Proc. Natl. Acad. Sci. 98(20):11462-11467.
Zhu, B.J. and A.H. Conney (1998) “Functional Role of Estrogen Metabolism in Target Cells: Review and Perspectives,”Carcinogenisis19)1):1-27.
Saliwanchik Lloyd & Saliwanchik
Smith Ruth S.
LandOfFree
Methods for reducing the risk of breast cancer in and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for reducing the risk of breast cancer in and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing the risk of breast cancer in and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3392194